We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Parkinson's Disease Risk Indicators Found in Diverse Tissues

By LabMedica International staff writers
Posted on 18 Aug 2016
Tiny changes in DNA that have been linked to Parkinson's disease, the second most common neurodegenerative disorder after Alzheimer's, were found not only in brain cells, where they were expected, but also in liver, fat, immune and developmental cells.

Parkinson’s disease (PD) is the second most common neurodegenerative disorder, affecting about 1% of those over the age of 60 and classically, PD was considered a movement disorder with akinesia, rigidity, tremor and postural instability as the predominant motor features.

Scientists at the Van Andel Research Institute (Grand Rapids, MI, USA) and their collaborators investigated single-nucleotide polymorphisms SNPS) which were integrated with comprehensive data from the Roadmap Epigenomics Mapping Consortium (REMC) for 77 tissues and cell types and 1000 genomes using FunciSNP software.

The team found 12 loci across several tissue types that were particularly enriched or full of SNPS indicating an increase in risk. More...
Only one locus was identified in the substantia nigra, the part of the brain where dopamine-producing neurons die. Other loci were found in liver, fat, immune and developmental cells. It is the first time this type of genome-wide analysis has been used to investigate Parkinson's disease.

Although much more work must be done to unravel exactly how these loci affect risk, there are interesting parallels between the team's findings and recent work done by others investigating Parkinson's. For example, three of the risk loci were found in immune cells, a promising finding as evidence suggests that Parkinson's may be linked to inflammation, the immune system's reaction to help fight off potential threats.

Patrik Brundin, MD, PhD, director of Center for Neurodegenerative Science and one of the study's authors, said, “Only a small percentage of Parkinson's cases are familial and have a clear and well-defined genetic inheritance. The remaining cases develop the disease seemingly at random. The emerging view is that Parkinson's is more of a syndrome, as a defined set of clinical symptoms and some shared features of brain pathology, with a diverse set of underlying causes. One surprising finding in our study is that only one gene locus was clearly linked to the brain while others were associated with tissues throughout the body. This supports the emerging theory that Parkinson's is a disorder that can be caused by disruptions in cellular processes in many locations, not just one. Furthermore, for the disease to develop in one person there has to be an unfortunate combination of a genetic predisposition and, as yet undefined, environmental insults.” The study was published on July 27, 2016, in the journal Scientific Reports.

Related Links:
Van Andel Research Institute


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-Time PCR System
Gentier 96T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.